Table 2
HPV status and telomerase PCR ELISA assay absorbance read at 450 nm with a reference wavelength of 690 (A450) versus histological background of benign cervices (n=19) and histological diagnosis, stage, and lymph node status of cervical carcinoma (n=20)
| Benign cervices | Cervical carcinoma | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Case | Histological background | A450 | HPV | Case | Histological diagnosis | Stage | LN | A450 | HPV |
| ELISA, enzyme linked immunosorbent assay; LN, lymph node status; NA, information not available. | |||||||||
| 1 | Uterovaginal prolapse | −0.032 | L1 | 1 | Squamous, non-keratinising | II | – | 1.469 | L1 |
| 2 | Leiomyoma | −0.028 | – | 2 | Squamous, non-keratinising | I | – | 3.781 | 16 |
| 3 | Leiomyoma | −0.069 | – | 3 | Squamous, non-keratinising | IV | + | 1.935 | 16 |
| 4 | Benign ovarian teratoma | 0.032 | – | 4 | Squamous, keratinising | I | NA | 1.841 | 16 |
| 5 | Leiomyoma | 0.081 | – | 5 | Squamous, keratinising | I | – | 0.173 | 16 |
| 6 | Leiomyoma | 0.135 | – | 6 | Squamous, keratinising | I | – | 0.209 | L1 |
| 7 | Leiomyoma | 0.011 | – | 7 | Squamous, non-keratinising | II | NA | 3.163 | 16 |
| 8 | Benign ovarian teratoma | −0.017 | – | 8 | Squamous, non-keratinising | I | – | 1.632 | 6 |
| 9 | Uterovaginal prolapse | −0.020 | – | 9 | Adenocarcinoma | II | – | 0.178 | 16 |
| 10 | Adenomyosis | 0.038 | – | 10 | Adenocarcinoma | I | – | 0.017 | 16 |
| 11 | Placenta praevia | −0.073 | – | 11 | Squamous, non-keratinising | III | NA | 0.238 | 16 |
| 12 | Leiomyoma | 0.349 | – | 12 | Squamous, non-keratinising | II | NA | −0.006 | L1 |
| 13 | Ovarian serous cystadenoma | 0.096 | – | 13 | Squamous, non-keratinising | I | – | 0.067 | – |
| 14 | Uterovaginal prolapse | −0.002 | – | 14 | Squamous, non-keratinising | I | – | 21.790 | L1 |
| 15 | Leiomyoma | 0.015 | – | 15 | Lymphoepithelioma-like | I | – | 0.013 | 16 |
| 16 | Leiomyoma | 0.019 | – | 16 | Squamous, non-keratinising | III | NA | 3.045 | 16 |
| 17 | Endometrial polyp | 0.006 | – | 17 | Squamous, keratinising | I | – | 0.075 | 16 |
| 18 | Uterovaginal prolapse | 0.012 | – | 18 | Adenosquamous | I | – | 0.222 | – |
| 19 | Uterovaginal prolapse | 0.003 | – | 19 | Squamous, keratinising | II | NA | −0.001 | 16 |
| 20 | Squamous, keratinising | II | NA | 0.630 | 16 | ||||
